Printer Friendly

CHERNE MEDICAL BECOMES VITAL HEART SYSTEMS; STRATEGIC MOVE TO BOSTON AREA IN AUGUST TO DEVELOP NEW PRODUCTS AND SERVICES

CHERNE MEDICAL BECOMES VITAL HEART SYSTEMS; STRATEGIC MOVE TO BOSTON
 AREA IN AUGUST TO DEVELOP NEW PRODUCTS AND SERVICES
 MINNEAPOLIS, May 29 /PRNewswire/ -- Cherne Medical, Inc. (NASDAQ: CHNE) announced approval of its new name, Vital Heart Systems, Inc., at its annual meeting held yesterday. It will begin trading under the NASDAQ symbol VHRT on June 1. Part of the strategic restructuring will include a move to the Boston area, with expansion of its work force and the development of several new products and services.
 "We developed an exciting new technology for detecting coronary artery disease (CAD), proved its clinical value and established a strong, promising market presence," said David L. Printy, chairman, president and CEO. "We are pleased to report today that we have had eight orders for the SV 4000 so far this calendar quarter."
 As of August 1, Vital Heart Systems' marketing, sales, research and development and administrative offices will be located at the new corporate headquarters in Danvers, Mass. Printy added, "We are now ready to take the knowledge we have gained and apply it to medical technologies which will improve patient outcome and help meet the urgent need to control health care costs.
 "The Boston area is a hotbed of emerging, state-of-the-art medical technology," said Printy. "Our connections with the Boston area medical community are extensive."
 Vital Heart Systems' board of directors includes Richard J. Cohen, M.D., Ph.D., director of the Harvard-MIT Center for Biomedical Engineering; Loren N. Vorlicky, M.D., senior vice president of Dartmouth-Hitchcock Medical Center and John Kordash, president and CEO of MediQual, located in Westborough, Mass.
 In addition, Joseph S. Alpert, M.D., FACC, vice chairman, Department of Medicine at the University of Massachusetts Medical Center, was recently named to Vital Heart Systems' medical advisory board.
 Cherne Medical manufactures and markets the Variance Cardiograph, a non-invasive, stress-free diagnostic instrument capable of identifying coronary artery disease even when no symptoms are present.
 -0- 5/29/92
 /CONTACT: David L. Printy of Cherne, 612-933-2838/
 (CHNE VHRT) CO: Cherne Medical, Inc.; Vital Heart Systems, Inc. ST: Minnesota; Massachusetts IN: MTC SU: PDT


KH -- MN001 -- 5064 05/29/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 29, 1992
Words:358
Previous Article:FISHER BUSINESS SYSTEMS, INC. ANNOUNCES FIRST QUARTER RESULTS
Next Article:DOWNEY SAVINGS APPOINTS ANGELIKA MAYMAN AS INVESTOR RELATIONS MANAGER
Topics:


Related Articles
CHERNE MEDICAL, INC. REDUCES THIRD QUARTER LOSS BY 25 PERCENT AND LOSS FOR NINE-MONTH PERIOD ENDED SEPT. 30, 1991 BY 33 PERCENT
CHERNE ANNOUNCES FIRST CLOSING OF ITS EQUITY PLACEMENT
MAJOR IMPROVEMENT IN DIAGNOSIS OF HEART ATTACKS IN EMERGENCY DEPARTMENT USING CHERNE VARIANCE CARDIOGRAPH DOCUMENTED BY MINNEAPOLIS RESEARCH
VITAL HEART SYSTEMS REPORTS COMMUNICATION FROM FDA
CASCADE MEDICAL SIGNS AGREEMENT WITH BOSTON ADVANCED TECHNOLOGIES
VITAL HEART SYSTEMS ENTERS INTO EXCLUSIVE OPTION AGREEMENT TO PURCHASE NEW TECHNOLOGY
VITAL HEART SYSTEMS APPOINTS SENIOR EXECUTIVES TO MANAGE AND DIRECT SALES
VITAL HEART SYSTEMS' RECENTLY ELECTED PRESIDENT & CEO AND EXECUTIVE VICE PRESIDENT ARE ELECTED TO BOARD OF DIRECTORS
VITAL HEART SYSTEMS AND BETH ISRAEL HOSPITAL TO EVALUATE NEW INSTRUMENT FOR PATIENTS AT RISK FOR 'SUDDEN DEATH'
BOSTON SCIENTIFIC POSITIONS SELF TO GROW WITH ACQUISITIONS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters